Ranbaxy arm launches Atorvastatin generics in Malaysia

Ranbaxy Malaysia Sdn Bhd. (RMSB), the wholly-owned subsidiary of Ranbaxy Laboratories, today announced the launch of the first generics version of Atorvastatin under the brand name Storvas in Malaysia.

According to a release issued by Ranbaxy to the BSE today, RMSB had earlier received approvals to market generic Oseltamavir, and was awarded a contract for supply to the Malaysian government.

T. Jeyabalan, managing director of RMSB, said: "Ranbaxy is proud to be the first company to launch the generic alternatives of Atorvastatin and Oseltamivir in Malaysia. It is our constant endeavour to offer affordable and safe generics of high quality to patients in Malaysia and provide support to the government's healthcare plan."